17 okt: Gate Ventures PLC – optagelse til handel af nye aktier
17 okt: Salg af ejendom og opjustering af forventning til årsresultat for..
17-10-2017 12:52:19

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017

Relateret indhold
12 sep - 
Onsdagens aktier: William Demant til vejrs uden nyt i g..
12 sep - 
Onsdagens aktier: William Demant til vejrs uden nyt i g..
10 sep - 
Mandagens aktier: Danske Bank tog igen bunden i afvente..
Relateret debat
20:07 - 
Jeg vidste der var noget med den å :-) For min skyld må..
19:57 - 
@birketvedhotmailcom Det er ogsaa vaerd at bemaerke, at..
19:53 - 
@MarkusK Jeg tror, at @johnwestergaard mente, at du ikk..

Company Announcement 

  • Net sales of DARZALEX in the third quarter of 2017 totaled USD 317 million

  • Genmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. 

Copenhagen, Denmark; October 17, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 317 million in the third quarter of 2017. Net sales were USD 230 million in the U.S. and USD 87 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX. 

About DARZALEX® (daratumumab)

DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.  In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for treatment of adults with relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market.  For more information, visit www.DARZALEX.com

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.  A comprehensive clinical development program, including multiple Phase III studies, is ongoing with daratumumab in relapsed and frontline multiple myeloma settings, and additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant diseases on which CD38 is expressed, such as smoldering myeloma, NKT-cell lymphoma, amyloidosis, myelodysplastic syndromes and solid tumors.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.     

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc. 

1 DARZALEX Prescribing information, June 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf  Last accessed June 2017

2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.

3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.

4 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.

5 Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012; 120(21):abstract 2974.

Company Announcement no. 34

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13:04
GEN
Janssen præsenterer også kliniske data for deres bispecifikke antistof cMET/EGFR den 25 september og..
5
16 sep
GEN
Eliot - har stor respekt for dig, - iøvrigt mener jeg at alle nævnte deltager i større eller mindre ..
5
12 sep
GEN
Det er mit indtryk, at de fleste mener at næste vigtige trigger er resultaterne af MAIA studiet. Det..
4
19:53
GEN
@MarkusK Jeg tror, at @johnwestergaard mente, at du ikke skulle debattere med @birketvedhotmailcom. ..
2
13 sep
GEN
Mon ikke det er en blanding af fornuft, snarlige MAIA data og Jans powertalk i aftes?
2
13 sep
GEN
Nyheder , opkøb ...? . Opføre sig lidt atypisk ...
2
19:18
GEN
Ja det er den samme.  Han lukkede sin fund i 2001 så de "tricks" han beskriver er omkring 20 år gaml..
1
19:16
GEN
Det banale spørgsmål er så som sædvanlig: Prøv at fremlægge de handler du mener der er shortere og h..
1
16 sep
GEN
Novo er da ikke manipuleret (af shortere) og den er da ikke specielt bullish.
1
16 sep
GEN
Et hurtigt kig på kursudviklingen for manipulerede aktier viser, at du tilsidesætter fakta og data, ..
1

Coloplast/dir: Skift i ambitionsniveauet er afgørende for væksten

18-09-2018 15:10:18
Den danske medicokoncern Coloplast har taget de første skridt i strategien om at få højere priser for klinisk dokumenterede produkter, og det kommer til at spille en afgørende rolle for selskabets vækst i fremtiden.- Det er ekstremt vigtigt. Vi opfatter det her skifte i ambitionsniveauet som afgørende for, at vi kan forøge vækstmomentum, siger Kristian Villumsen, der er direktør for den kroniske f..

Mærsk/analytikere: Frasalg trak lidt ud men er nu så godt som i mål

18-09-2018 13:45:01
Når A.P. Møller-Mærsk næste år er klar til at sende Maersk Drilling, som ejer rigge og skibe, der borer efter olie og gas til havs på vegne af olieselskaberne, på børsen som et selvstændigt selskab, er koncernen også så godt som i mål med den ene del af strategien, som blev lanceret i 2016.På lørdag er det præcis to år siden, at Mærsk løftede sløret for en ny strategi, der skulle være med til at t..

Mærsk/analytikere: Strategiske ændringer skal samle selskabet i ét

18-09-2018 11:15:00
Mærsk-koncernen rammer i denne uge toårsdagen for lanceringen af den nye strategi, hvor selskabet blev samlet i to enheder - en for transport- og logistikaktiviteter og en for energiaktiviteter.Og mens planerne for energiaktiviteterne, der efter planen skal udskilles helt, er ved at være fuldbragte, resterer der fortsat en del arbejde med transport- og logistikforretningen, hvor flagskibet stadig ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Spændingen stiger omkring Danske Bank
2
Pandora: Stiger på rygter i markedet om muligt bud - NY
3
Aktier/middag: Pandora banket op af italienske rygter
4
Novo Nordisk reorganiserer R&D - 400 medarbejdere afskediges - NY
5
Pandora/Sydbank: Lav værdisætning kan udnyttes af kapitalfonde

Relaterede aktiekurser

Genmab A/S 1.044,50 -1,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. september 2018 21:38:58
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180917.3 - EUROWEB4 - 2018-09-18 21:38:58 - 2018-09-18 21:38:58 - 1 - Website: OKAY